Literature DB >> 9218232

Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals.

A Roth1, I Hogan, C Farren.   

Abstract

PURPOSE: The success rate of a treatment program tailored to opioid-abusing health-care professionals that included oral naltrexone and group therapy was studied.
METHODS: 20 opioid-abusing health professionals were treated over a 5-year-period. Clients received an initial assessment, supervised administration of naltrexone, and weekly attendance at a psychotherapy group for health professionals. Naltrexone was administered for the first several months, then patients continued the program without naltrexone.
RESULTS: 18 patients were referred to the program after being caught diverting medication. Two patients came spontaneously. Of the 18 referred patients, 12 had no relapses, and 5 had only one relapse, followed by long-term sobriety. Mean overall duration of naltrexone administration was 8 months, and the mean duration in the program was 1.9 years. 94% of referred clients had long term abstinence, and 66% were working in their profession during the program.
CONCLUSIONS: Naltrexone in the setting of a structured program is helpful in the treatment and professional reinstatement of opioid abusing health professionals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218232     DOI: 10.1016/s0740-5472(96)00164-x

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  11 in total

Review 1.  Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.

Authors:  Evgeny Krupitsky; Edwin Zvartau; George Woody
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

Review 2.  Antagonist Models for Relapse Prevention and Reducing HIV Risk.

Authors:  George E Woody; Evgeny Krupitsky; Edwin Zvartau
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-27       Impact factor: 4.147

Review 3.  Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

Authors:  Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland
Journal:  Lancet       Date:  2010-07-31       Impact factor: 79.321

4.  Preparation and investigation of sustained drug delivery systems using an injectable, thermosensitive, in situ forming hydrogel composed of PLGA-PEG-PLGA.

Authors:  Elham Khodaverdi; Farnaz Sadat Mirzazadeh Tekie; Seyed Ahmad Mohajeri; Fariba Ganji; Gholamhossein Zohuri; Farzin Hadizadeh
Journal:  AAPS PharmSciTech       Date:  2012-04-18       Impact factor: 3.246

5.  A randomized trial of oral naltrexone for treating opioid-dependent offenders.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Arthur I Alterman; Charles P O'Brien
Journal:  Am J Addict       Date:  2010 Sep-Oct

Review 6.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

Review 7.  Medications for substance use disorders.

Authors:  Antoine B Douaihy; Thomas M Kelly; Carl Sullivan
Journal:  Soc Work Public Health       Date:  2013

8.  Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.

Authors:  Paul H Earley; Jacqueline Zummo; Asli Memisoglu; Bernard L Silverman; David R Gastfriend
Journal:  J Addict Med       Date:  2017 May/Jun       Impact factor: 3.702

Review 9.  Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.

Authors:  Adam Bisaga; Paolo Mannelli; Maria A Sullivan; Suzanne K Vosburg; Peggy Compton; George E Woody; Thomas R Kosten
Journal:  Am J Addict       Date:  2018-04

Review 10.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.